MorphoSys and Shionogi Agree Three-Year Extension of Research Partnership
MorphoSys AG announced that it has expanded its current licence agreement withShionogi & Co., Ltd., Osaka, Japan. The expanded agreement covers the use of MorphoSys'sHuCALantibody technology and additional proprietary technology modules for research in drug discovery for three additional years and will be run by the company'sAbD Serotecunit. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's patented antibody library HuCAL PLATINUM for research purposes at one of its research sites. MorphoSys will receive annual user fees from Shionogi for access to the technologies. Further financial details were not disclosed.
"We are very pleased with Shionogi's decision to continue using our HuCAL antibody technology in drug discovery. Their long-term commitment to HuCAL as a research tool proves the clear scientific and commercial potential the HuCAL technology has beyond acting as a source of therapeutic antibodies," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.
MorphoSys and Shionogi signed a first license agreement on the use of MorphoSys's HuCAL technology in September 2005.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Scientists adapt astronomy method to unblur microscopy images - New method to generate clearer images of thick biological samples
BioMerieux to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
